Assessing the cost of parathyroidectomy 2010 FOTHERINGHAM.pdf (174.12 kB)

Assessing the cost of parathyroidectomy as a treatment for uncontrolled secondary hyperparathyroidism in stage 5 chronic kidney disease

Download (174.12 kB)
posted on 25.02.2020, 10:52 by James Fotheringham, Alejandra Duenas, Andrew Rawdin, Martin Wilkie, B. Harrison, Ronald Akehurst
Conventional therapy for chronic kidney disease mineral bone disorder includes control of serum phosphate with phosphate binders and the supplementation of activated vitamin D. In many cases this proves inadequate, and in the UK parathyroidectomy (PTX) is recommended for patients who are otherwise surgical fit as it is perceived as less costly than calcimemetics. However, no details of the true cost of PTX have been published. AIMS: To describe the healthcare resource use and costs associated with patients receiving PTX as a treatment for uncontrolled secondary hyperparathyroidism in a single UK National Health Service (NHS) centre (Sheffield Kidney Institute).



There is no personal data or any that requires ethical approval


The data complies with the institution and funders' policies on access and sharing

Sharing and access restrictions

The data can be shared openly

Data description

  • The file formats are open or commonly used

Methodology, headings and units

  • Headings and units are explained in the files

Usage metrics

School of Health and Related Research - HEDS